EUVIMEDEUVIMED entdecken
Open Access

Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome

Ana Sanchez-Azofra, Wanjun Gu, Jorge A Masso-Silva, David Sanz-Rubio, Marta Marin-Oto, Pablo Cubero, Ana V Gil, Esteban A Moya, Laura A Barnes, Omar A Mesarwi, Traci Marin, Tatum S Simonson und 3 weitere

Journal of Clinical Sleep Medicine · 2023

DOI: 10.5664/jcsm.10600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Sleep Medicine, 2023. Verfasst von Ana Sanchez-Azofra und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Pulmonary Disease, Chronic Obstructive, Autoimmune Diseases. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY OBJECTIVES: The coexistence of obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) in a single individual, also known as overlap syndrome (OVS), is associated with higher cardiovascular risk and mortality than either OSA or COPD alone. However, the underlying mechanisms remain unclear. We hypothesized that patients with OVS have elevated systemic inflammatory biomarkers relative to patients with either disease alone, which could explain greater cardiovascular risk observed in OVS. METHODS: We included 255 participants in the study, 55 with COPD alone, 100 with OSA alone, 50 with OVS, and 50 healthy controls. All participants underwent a home sleep study, spirometry, and a blood draw for high-sensitivity C-reactive protein and total blood count analysis. In a randomly selected subset of 186 participants, inflammatory protein profiling was performed using Bio-Rad Bio-Plex Pro Human Cytokine 27-Plex Assays. Biomarker level differences across groups were identified using a mixed linear model. RESULTS: Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and granulocyte colony stimulating factor (G-CSF) were higher in participants with OVS and COPD compared with healthy controls and participants with OSA. Furthermore, participants with OVS had higher circulating levels of leukocytes and neutrophils than those with COPD, OSA, and controls. CONCLUSIONS: COPD and OVS are associated with higher systemic inflammation relative to OSA and healthy controls. This work proposes the potential utilization of interleukin 6, granulocyte colony stimulating factor, and high-sensitivity C-reactive protein as screening biomarkers for COPD in patients with OSA. Inflammatory pathways may not fully explain the higher cardiovascular risk observed in OVS, indicating the need for further investigation. CITATION: Sanchez-Azofra A, Gu W, Masso-Silva JA, et al. Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome. J Clin Sleep Med. 2023;19(8):1447-1456.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveSleep Apnea SyndromesPulmonary Disease, Chronic ObstructiveAutoimmune DiseasesHumansC-Reactive ProteinInterleukin-6InflammationBiomarkersGranulocyte Colony-Stimulating Factor

Stichwörter der Autor:innen

c-reactive proteincardiovascular riskchronic obstructive pulmonary diseasegranulocyte colony stimulating factorinterleukin 6interleukin 8obstructive sleep apneaoverlap syndromesleep-disordered breathing

Substanzen

C-Reactive ProteinInterleukin-6BiomarkersGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care, and Sleep Medicine and Physiology, Department of Medicine, University of California, La Jolla, California.
  • Division of Pulmonary and Sleep Medicine. Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, España.
  • Herbert Wertheim School of Public Health and Longevity Sciences, University of California, San Diego, La Jolla, California.
  • Section of Pulmonary and Critical Care, VA San Diego, La Jolla, California.
  • Translational Research Unit, IIS Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Health Sciences, Department of Respiratory Therapy, Victor Valley College, Victorville, California.

Förderung

  • BLRD VA
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIA NIH HHS

Zitieren

APA

Sanchez-Azofra, A., Gu, W., Masso-Silva, J. A., Sanz-Rubio, D., Marin-Oto, M., Cubero, P., Gil, A. V., Moya, E. A., Barnes, L. A., Mesarwi, O. A., Marin, T., Simonson, T. S., Crotty Alexander, L. E., Marin, J. M., & Malhotra, A. (2023). Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.10600

Vancouver

Sanchez-Azofra A, Gu W, Masso-Silva JA, Sanz-Rubio D, Marin-Oto M, Cubero P, et al. Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome. Journal of Clinical Sleep Medicine. 2023. doi:10.5664/jcsm.10600

BibTeX
@article{SanchezAzofra2023,
  author = {Sanchez-Azofra, Ana and Gu, Wanjun and Masso-Silva, Jorge A and Sanz-Rubio, David and Marin-Oto, Marta and Cubero, Pablo and Gil, Ana V and Moya, Esteban A and Barnes, Laura A and Mesarwi, Omar A and Marin, Traci and Simonson, Tatum S and Crotty Alexander, Laura E and Marin, Jose M and Malhotra, Atul},
  title = {Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome},
  journal = {Journal of Clinical Sleep Medicine},
  year = {2023},
  doi = {10.5664/jcsm.10600}
}
Kostenlos starten →